Dishman Carbogen receives EIR from USFDA for Bavla facility

29 Jan 2019 Evaluate

Dishman Carbogen Amcis has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its Bavla facility, after successfully inspected by the USFDA in October 2018.

Thus, the company's facilities in Bavla and Naroda in India, multiple facilities in Switzerland and the Netherlands continue to be approved by the USFDA.

Dishman Carbogen Amcis provides innovative solutions for the development and supply of drug substances and drug products to the pharmaceutical and biopharmaceutical industries.

Dishman Carbogen Amc Share Price

159.50 0.95 (0.60%)
10-Mar-2026 10:15 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1819.00
Dr. Reddys Lab 1316.55
Cipla 1324.00
Zydus Lifesciences 918.80
Lupin 2341.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×